Professional Media briefs: August 2013

Share this article:
Timothy Cote
Timothy Cote

Scientific Communications Group launched the online Journal of Rare Dis­orders. The publisher said in a statement that the publication is the first US journal dedicated to rare diseases. SCG expects patient advocates, pharmaceutical companies and HCPs to be among its readers. Former director of the Office of Orphan Drug Development Timothy Cote and Ian Phillips of the Keck Graduate Institute are co-editors.

Elsevier's Health Care: The Journal of Delivery Science and Innovation launched in June and focuses on payment reform, patient-centered innovation and process improvement. Deputy Assistant Director for Health at the Congressional Budget office Melinda Buntin and associate professor of Medicine at the University of Pennsylvania's medical school edited the quarterly journal's inaugural issue.

The American Medical Association reorganized its communications team, including the onboarding of now-former GolinHarris executive director Debbie Harvey, reports PRWeek. Justin DeJong has signed onto the team as VP for editorial and channel strategy, after a stint as PR director of the US Department of Agriculture.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?